AUPH Aurinia Pharma: Forward P/S Multiple

Corporate emblem and logo of Aurinia Pharmaceuticals (AUPH)

Is it worth investing in Aurinia Pharmaceuticals (AUPH), given shareholder skepticism toward management and the absence of mergers? This forward P/S chart for Aurinia Pharmaceuticals (AUPH) illustrates the trend of expectations, where the 13.10 level represents the current value. The business relies on production outsourcing via Lonza, making drug manufacturing dependent on logistics. Ultimately, Aurinia Pharmaceuticals (AUPH) remains an authoritative developer of targeted therapy, deeply respected by nephrologists.

AUPH (Aurinia Pharmaceuticals Inc.) Forward P/S Multiple history from 07/04/2022 to 11/17/2026

Analytical breakdowns for Aurinia Pharmaceuticals

- current price and projected stock value:
Fundamental company valuation:Aurinia Corp AUPH
Product sample of Aurinia Pharmaceuticals

The fair value assessment of the asset is based on the ratio of market price to expected earnings. This indicator compares current capitalization with the one-year revenue forecast, determining the cost of each dollar of future sales. By analyzing the forward P/S ratio, an investor identifies whether the security is overbought or undervalued. For Aurinia Pharmaceuticals (AUPH), growth of this multiple may be limited by geopolitical risks and the disruption of clinical trials in sanctioned zones.

Analysis of competing companies

Forward P/S Multiple ARGX (argenx.com)|BioNTech Group (BNTX) - Market Cap to Future Revenue Ratio|ABIVAX - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Immunovant Inc|Price-to-Projected Revenue Ratio Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Therapeutics)|Price-to-Projected Revenue Ratio BioCryst Pharmaceuticals BCRX|Forward Price to Sales VERA|Dianthus Pharma - Forward P/S Multiple|PHVS - Forward P/S Multiple|ABCL: Forward P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Intrexon|PHAR - Projected Price to Revenue|Forward P/S Multiple NKTR|Price-to-Projected Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Projected Revenue Ratio Zenas Biopharma, Inc. ZBIO|Market Cap to Expected Sales Ratio immunome.com (IMNM)|Gossamer Bio Inc - Forward P/S Multiple|Forward Price to Sales KALV (KalVista Pharmaceuticals, Inc.)|SEPN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pieris Pharmaceuticals Inc|Forward Price-to-Revenue Multiple SVRA|Forward Price-to-Revenue Multiple Rigel Pharmaceuticals (RIGL)|Forward P/S Multiple ANAB|ATXS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio enGene Corp ENGN|Market Cap to Expected Sales Ratio RAPT Therapeutics, Inc. (RAPT)|Aerovate - Forward P/S Multiple|ACRS - Forward P/S Multiple|KYTX (Kyverna Therapeutics) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Tiziana Life Sciences Ltd. (TLSA)|Forward Price-to-Revenue Multiple CABA|Ventyx Biosciences (VTYX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Forward Price to Sales|Forward P/S Multiple ELDN (eledon.com)|AGEN - Forward Price-to-Revenue Multiple|CLYM - Price-to-Projected Revenue Ratio|Future Price to Revenue ZURA|ATYR: Forward P/S Multiple|Adagene Corp (ADAG) - Forward P/S Multiple|Forward Price-to-Revenue Multiple IMA|Shattuck Labs, Inc. - Future Price to Revenue|Price-to-Projected Revenue Ratio Equillium Inc (EQ)|Forward P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Projected Revenue Ratio Immunic, Inc. IMUX|Forward P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Projected Revenue Ratio|XFOR: Price-to-Projected Revenue Ratio|ACET: Forward P/S Multiple|CELU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio inmunebio.com|Market Cap to Projected Revenue BRNS (barinthusbio.com)|Forward P/S Multiple KZR|Forward P/S Multiple SAB Biotherapeutics, Inc (SABS)|Forward P/S Multiple AKTX (Akari Therapeutics, Plc)|Forward P/S Multiple enlivex.com ENLV|QTTB: Forward Price-to-Revenue Multiple|GOVX - Forward P/S Multiple|Edesa Biotech Inc (EDSA) - Price-to-Projected Revenue Ratio|IBIO - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio carismatx.com|XTLB: Forward Price to Sales|Price-to-Projected Revenue Ratio Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio aptevotherapeutics.com APVO|AIM - Forward Price-to-Revenue Multiple|Aditxt - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Corporation GRI|xortx.com (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio reshapelifesciences.com (HIND)|Price-to-Projected Revenue Ratio Revelation Bio|Market Cap to Future Revenue Ratio Indaptus Therapeutics, Inc. INDP|Price-to-Projected Revenue Ratio BiondVax Pharmaceuticals (SCNI)|Forward Price-to-Revenue Multiple CalciMedica CALI|Price-to-Projected Revenue Ratio Affimed AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA Pharma, Inc. - Forward P/S Multiple|Forward Price to Sales IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Corp (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple thirdharmonicbio.com